Keros Therapeutics Inc
Research Keros Therapeutics Inc (KROS) on Bullrun: market cap USD 231.58M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerKROS
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 231.58M
- Financial periodQ2 2026
- RevenueUSD 0
- Net income-USD 28.71M
- Free cash flow-USD 20.58M
Valuation Snapshot
latest market cap is USD 231.58M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 244.06M | USD 87.01M | USD 105.95M | n/a | 2.3 | USD 287.42M | USD 16.88M | USD 303.13M |
| FY2024 | USD 3.55M | -USD 187.35M | -USD 162.80M | n/a | -5 | USD 559.93M | USD 18.86M | USD 571.55M |
| FY2023 | USD 151.00K | -USD 152.99M | -USD 126.97M | n/a | -5.2 | USD 331.15M | USD 14.44M | USD 332.21M |
| FY2022 | USD 0 | -USD 104.68M | -USD 71.30M | n/a | -4.15 | USD 279.05M | USD 670.00K | USD 277.42M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 231.58M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 397.91M | 11.2 | n/a | n/a |
| 2024 | 2024-12-31 | USD 641.98M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 1.19B | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 1.32B | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 1.40B | n/a | n/a | n/a |
About Keros Therapeutics Inc
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients with disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. It develops rinvatercept, which acts as a ligand trap and inhibits the biological effects of myostatin and activin A in Phase 1 clinical trials for Duchenne Muscular Dystrophy and Amyotrophic Lateral Sclerosis;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Keros Therapeutics Inc's market cap?
Keros Therapeutics Inc's market capitalization is USD 231.58M.
What does Keros Therapeutics Inc do?
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients with disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States.